Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: semaglutide


Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk

May 17th 2022

Adding semaglutide to SoC was associated with a gain in life-years free of CVD events that was dependent on baseline CVD risk and age at treatment initiation. This study helps contextualize the results of semaglutide clinical trials (Diabetes Care)

Categories: Cardiovascular, Medication, News
Tags: semaglutide, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: semaglutide, Type 2 Diabetes

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

May 1st 2022

These findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: GLP-1RA, PIONEER 6, semaglutide, SUSTAIN 6

Categories: Cardiovascular, Medication
Tags: GLP-1RA, PIONEER 6, semaglutide, SUSTAIN 6

Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension

April 20th 2022

One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic parameters (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: semaglutide, STEP 1, weight gain

Categories: Medication
Tags: semaglutide, STEP 1, weight gain

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme

April 5th 2022

Oral semaglutide demonstrated consistently greater HbA1c and body weight reductions across a range of patient characteristics, with greater HbA1c reductions seen at higher baseline HbA1c levels (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: HbA1c, PIONEER, semaglutide

Categories: Medication
Tags: HbA1c, PIONEER, semaglutide

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

February 8th 2022

Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: semaglutide, Type 2 Diabetes

Categories: Medication
Tags: semaglutide, Type 2 Diabetes

Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials

December 16th 2021

In patients with T2D, semaglutide/liraglutide offered kidney-protective effects, which appeared more pronounced in those with pre-existing chronic kidney disease (Circulation)

Categories: Medication, Nephropathy, News
Tags: GIP–GLP1-Receptor Agonists, liraglutide, semaglutide, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: GIP–GLP1-Receptor Agonists, liraglutide, semaglutide, Type 2 Diabetes

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study

September 28th 2021

Patients receiving OW semaglutide experienced statistically significant and clinically relevant reductions from baseline in HbA1c and body weight. These results are in line with those of the SUSTAIN RCTs and support the use of OW semaglutide in routine clinical practice in adults with T2D in the UK (Diabetes Therapy)

Categories: Medication, News
Tags: HbA1c, semaglutide, Type 2 Diabetes

Categories: Medication
Tags: HbA1c, semaglutide, Type 2 Diabetes

Advances in GLP-1 treatment: focus on oral semaglutide

September 16th 2021

Oral semaglutide effectively reduces glycated hemoglobin (HbA1c) levels and body weight in a broad spectrum of patients with T2D and shows cardiovascular safety (Diabetology & Metabolic Syndrome)

Categories: Medication, News
Tags: GLP1, HbA1c, semaglutide, Type 2 Diabetes

Categories: Medication
Tags: GLP1, HbA1c, semaglutide, Type 2 Diabetes

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE)

July 23rd 2021

Semaglutide 2·0 mg was superior to 1·0 mg in reducing HbA1c, with additional bodyweight loss and a similar safety profile. This higher dose provides a treatment intensification option for patients with type 2 diabetes treated with semaglutide in need of additional glycaemic control (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: semaglutide, Type 2 Diabetes

Categories: Medication
Tags: semaglutide, Type 2 Diabetes

Semaglutide’s Success Could Usher in a “New Dawn” for Obesity Treatment

July 13th 2021

Despite obesity specialists’ enthusiasm for the drug’s potential, they also described major barriers to uptake and accessibility. Those barriers, they say, are rooted in the sordid legacy of weight-loss drugs and outdated notions of obesity (JAMA)

Categories: News, Obesity
Tags: semaglutide

Categories: Obesity
Tags: semaglutide

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

July 1st 2021

In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks (NEJM)

Categories: Medication, News
Tags: semaglutide, tirzepatide

Categories: Medication
Tags: semaglutide, tirzepatide

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study

June 3rd 2021

These data indicate prevalent early adoption of oral semaglutide in primary care, demonstrate real-world improvements in glycaemic control, and identify potential treatment gaps (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: IGNITE, semaglutide

Categories: Medication
Tags: IGNITE, semaglutide

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

March 24th 2021

Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks (JAMA)

Categories: News, Obesity
Tags: semaglutide

Categories: Obesity
Tags: semaglutide

Once-Weekly Semaglutide in Adults with Overweight or Obesity

February 11th 2021

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight (NEJM)

Categories: Medication, News, Obesity
Tags: semaglutide

Categories: Medication, Obesity
Tags: semaglutide

Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis

August 26th 2020

This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy (Journal of Clinical Endocrinology & Metabolism)

Categories: Medication, News
Tags: Empagliflozin, metformin, semaglutide, Type 2 Diabetes

Categories: Medication
Tags: Empagliflozin, metformin, semaglutide, Type 2 Diabetes

Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?

August 20th 2020

In clinical trials, oral semaglutide 14 mg reduced mean HbA1c by approximately 1.1–1.5% and reduced body weight by up to 5 kg. The most common side effects were gastrointestinal, mainly mild-to-moderate and transient nausea. Oral semaglutide may offer a practical and effective means of managing people living with T2D who require treatment intensification, and may change the paradigm of care in the primary care setting (Primary Care Diabetes)

Categories: Medication, News
Tags: semaglutide, Type 2 Diabetes

Categories: Medication
Tags: semaglutide, Type 2 Diabetes

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

August 18th 2020

This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability (Diabetes Therapy)

Categories: Medication, News
Tags: Glucagon-Like Peptide 1 Receptor Agonist, semaglutide, Type 2 Diabetes

Categories: Medication
Tags: Glucagon-Like Peptide 1 Receptor Agonist, semaglutide, Type 2 Diabetes

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

June 3rd 2020

This implies that liraglutide and semaglutide may be beneficial for patients with type 2 diabetes, irrespective of their baseline BP (Diabetes Obesity and Metbolism)

Categories: Medication, News
Tags: liraglutide, semaglutide

Categories: Medication
Tags: liraglutide, semaglutide

Oral semaglutide for type 2 diabetes: a systematic review and meta‐analysis

October 22nd 2019

Oral semaglutide can effectively and safely reduce blood glucose, body weight and systolic blood pressure. Nevertheless, it is associated with increased incidence of gastrointestinal adverse events (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: semaglutide, Type 2 Diabetes

Categories: Medication
Tags: semaglutide, Type 2 Diabetes

Efficacy, Safety and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin ± Metformin in Patients with Type 2 Diabetes: the PIONEER 8 Trial

September 17th 2019

Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin ± metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide-1 receptor agonists (Diabetes Care)

Categories: Medication, News
Tags: insulin, metformin, PIONEER, semaglutide

Categories: Medication
Tags: insulin, metformin, PIONEER, semaglutide
  • 1
  • 2
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Napp DiabetesNovo NordiskBoehringer IngelheimAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAbout Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership